BCL2L1 and leukemia: Zhou and his coworkers linked ABT263 to VHL ligand to develop the PROTAC DT2216, which effectively degraded Bcl-xL and suppressed Bcl-xL-dependent leukemia cells in vitro and in vivo, without causing thrombocytopenia due to the poor expression of VHL in platelets [167].